Your browser doesn't support javascript.
loading
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Finn, Richard S; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang; Bodoky, György; Pracht, Marc; Yokosuka, Osamu; Rosmorduc, Olivier; Gerolami, René; Caparello, Chiara; Cabrera, Roniel; Chang, Charissa; Sun, Weijing; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Bruix, Jordi.
Affiliation
  • Finn RS; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: rfinn@mednet.ucla.edu.
  • Merle P; Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France.
  • Granito A; Department of Medical and Surgical Sciences, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
  • Huang YH; Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Bodoky G; Department of Oncology, St Laszlo Teaching Hospital, Budapest, Hungary.
  • Pracht M; Service d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.
  • Yokosuka O; Department of Gastroenterology and Nephrology, Chiba University, Chiba, Japan.
  • Rosmorduc O; Department of Gastroenterology and Hepatology, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie, Sorbonne Universités, Paris, France.
  • Gerolami R; Service d'Hépato-gastroentérologie, CHU Timone, Université de la Méditerranée, Marseille, France.
  • Caparello C; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Cabrera R; University of Florida, Hepatology, UF Health Cancer Center, Gainesville, FL, USA.
  • Chang C; Liver Cancer Program, Division of Liver Diseases, Mount Sinai Medical Center, New York, NY, USA.
  • Sun W; Medical Oncology Division, University of Kansas School of Medicine, Kansas City, KS, USA.
  • LeBerre MA; Bayer HealthCare SAS, Loos, France.
  • Baumhauer A; Bayer AG, Leverkusen, Germany.
  • Meinhardt G; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
  • Bruix J; BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain. Electronic address: jbruix@clinic.ub.es.
J Hepatol ; 69(2): 353-358, 2018 08.
Article in En | MEDLINE | ID: mdl-29704513
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Pyridines / Carcinoma, Hepatocellular / Sorafenib / Liver Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Pyridines / Carcinoma, Hepatocellular / Sorafenib / Liver Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2018 Type: Article